I-SQUARED-CAPITAL
9.12.2020 17:02:08 CET | Business Wire | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund II, has acquired and combined Infofabrica Holdings Pte Ltd and Cloud Kinetics Tech Pte Ltd, two Cloud migration services companies based in Singapore. The combined businesses are poised to become a leading Cloud migration and managed services provider in Southeast Asia and India, providing capability across all major public Cloud operators. These investments are part of a new Asian Digital Infrastructure platform and will enable I Squared Capital’s Digital Infrastructure companies to offer comprehensive Cloud-based solutions to their customers. The Cloud platform will have a growing pool of over 300 professionals with deep experience in Cloud infrastructure, data, analytics, application modernization and Cloud management and possess a broad range of Cloud certifications.
“The future of data and computing will be driven by the corporate adoption of hybrid Cloud solutions through an orchestrated mix of on-premises infrastructure, co-location and Cloud services. Offering seamless and efficient migration to the hybrid Cloud relieves a critical bottleneck to Cloud adoption, especially in the Asia-Pacific region. The combination of Infofabrica and Cloud Kinetics will result in a powerful Cloud migration solution provider for our clients,” said Gautam Bhandari, Managing Partner of I Squared Capital. “With these acquisitions, our global investments and commitments to the Digital Infrastructure sector are over $2.6 billion and growing.”
Cloud migration consists of the specialized capabilities and technologies, undertaken by certified experts, to enable businesses to move to and operate on the Cloud seamlessly. IDC predicts that Southeast Asia’s Cloud computing market will reach $40 billion by 2025, underscoring its importance in our daily lives. The platform is co-founded and being led by Haji Munshi, a technology executive who has held senior leadership positions at Google Cloud, Cisco, Hewlett Packard Enterprise and Dell, and Tameem Ebrahim, ex-Founding Partner of Quvat Capital and was an investment banker at Merrill Lynch and Deutsche Bank in Southeast Asia.
“The debate on the need for Cloud has ended after the experience of the Covid-19 pandemic,” said Haji Munshi, Group CEO of InfoFabrica and Cloud Kinetics. “Whether businesses are developing and testing their new applications, scaling their online e-commerce offerings, or running their core business workloads, this is possible only because of the stable, scalable solutions offered by the public Cloud. The demand for technical capability to migrate to Cloud has far outstripped supply in Asia-Pacific thus far and the combined company will be a market leader in Cloud migration services.”
“We are really pleased to be partnering with I Squared Capital, their expertise and breadth in Asia, along with existing large-scale investments in telecoms and data centers, will certainly accelerate and move us closer to our vision to be the top cloud migration and managed services provider in the region,” commented Abu Bakar Mohd Nor, Chairman of IFF. “The complementary capabilities of InfoFabrica and Cloud Kinetics is key and part of our strategy to be an end-to-end Cloud specialist and also simplify our clients’ Cloud migration journey.”
About Infofabrica Holdings (https://www.infofabrica.com/ ): Founded in 2013, InfoFabrica Holdings Pte Ltd has operations in Singapore, Indonesia, Vietnam and Malaysia. InfoFabrica is a certified Cloud partner of Amazon Web Services, Google Cloud, IBM Cloud.
About Cloud Kinetics (https://www.Cloud-kinetics.com/ ): Founded in 2012, Cloud Kinetics Tech Pte Ltd has operations in Singapore, Thailand, India and the United States. Cloud Kinetics is a certified Cloud partner of Microsoft Azure, Amazon Web Services and Google Cloud.
About I Squared Capital (http://www.isquaredcapital.com/ ): I Squared Capital is an independent global infrastructure investment manager focusing on energy, utilities, digital infrastructure, transport and social infrastructure in the Americas, Europe and Asia. The firm has offices in Miami Hong Kong, London, New Delhi, New York, and Singapore.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom